Integrating Precision Medicine into Gynecological Cancer Treatment: A Path Toward Personalized Care

This study investigated the integration of precision medicine into gynaecological cancer treatment with the aim of assessing its impact on patient outcomes and identifying challenges to clinical adoption. A quantitative research design was employed, with data collected from 200 patients across tertiary hospitals, including 100 who received precision medicine–based therapies and 100 who underwent conventional treatment. Data were analyzed using SPSS through descriptive and inferential statistics. Results showed that patients in the precision medicine group achieved a significantly higher mean survival time (28.4 ± 6.5 months) compared to the conventional group (22.1 ± 7.2 months), with an independent samples t-test confirming statistical significance (t(198) = 2.89, p = 0.004). Additionally, Chi-square analysis revealed significant variations in perceptions of integration challenges across professional groups (χ² = 12.47, p = 0.014), while descriptive analysis identified future strategies such as genomic infrastructure investment (M = 4.6) and professional training (M = 4.4) as top priorities. These findings confirm that precision medicine improves survival outcomes in gynaecological oncology, but its clinical adoption remains constrained by technological, clinical, and ethical barriers. The study contributes to evidence-based practice by highlighting both the promise and the limitations of precision oncology, while providing clear directions for future research and policy development.